XERIS PHARMACEUTICALS INC
NASDAQ: XERS (Xeris Biopharma Holdings, Inc.)
Last update: 4 hours ago7.45
-0.22 (-2.87%)
| Previous Close | 7.67 |
| Volume | 1,598,308 |
| Price / Earnings (Forward) | 36.50 |
| Price / Sales | 4.01 |
| Price / Book | 107.68 |
| 52 Weeks Range |
| Profit Margin | -20.25% |
| Operating Margin (TTM) | -5.14% |
| Diluted EPS (TTM) | -0.290 |
| Quarterly Revenue Growth (YOY) | 47.90% |
| Current Ratio (MRQ) | 1.72 |
| Operating Cash Flow (TTM) | -26.71 M |
| Levered Free Cash Flow (TTM) | -5.90 M |
| Return on Assets (TTM) | -3.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Xeris Biopharma Holdings, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 4.19% |
| % Held by Institutions | 54.46% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HECHT BETH | - | 8.43 | -16,666 | -140,494 |
| MCCULLOCH KEVIN | - | 8.43 | -15,000 | -126,450 |
| PIEPER STEVEN | - | 8.43 | -5,000 | -42,150 |
| Aggregate Net Quantity | -36,666 | |||
| Aggregate Net Value ($) | -309,094 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 8.43 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PIEPER STEVEN | Officer | 01 Sep 2026 | Automatic sell (-) | 5,000 | 8.43 | 42,150 |
| HECHT BETH | Officer | 01 Sep 2026 | Automatic sell (-) | 16,666 | 8.43 | 140,494 |
| MCCULLOCH KEVIN | Officer | 01 Sep 2026 | Automatic sell (-) | 15,000 | 8.43 | 126,450 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |